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Alternative splicing is an important component of tumorigenesis. Recent advent of exon array technology
enables the detection of alternative splicing at a genome-wide scale. The analysis of high-throughput
alternative splicing is not yet standard and methodological developments are still needed. We propose
a novel statistical approach—Dually Constrained Correspondence Analysis—for the detection of splicing
changes in exon array data. Using this methodology, we investigated the genome-wide alteration of alter-
native splicing in patients with non-small cell lung cancer treated by bevacizumab/erlotinib. Splicing
candidates reveal a series of genes related to carcinogenesis (SFTPB), cell adhesion (STAB2, PCDH15,
HABP2), tumor aggressiveness (ARNTL2), apoptosis, proliferation and differentiation (PDE4D, FLT3,
IL1R2), cell invasion (ETV1), as well as tumor growth (OLFM4, FGF14), tumor necrosis (AFF3) or tumor
suppression (TUSC3, CSMD1, RHOBTB2, SERPINB5), with indication of known alternative splicing in a
majority of genes. DCCA facilitates the identification of putative biologically relevant alternative splicing
events in high-throughput exon array data.
 2015 Elsevier Inc. All rights reserved.1. Introduction
Alternative splicing (AS) is a major constituent of transcriptome
diversity which affects biological processes including a broad range
of pathological conditions.
The specific design of exon arrays makes it possible to investi-
gate genomic variations both at the gene and at the exon level. This
enables the identification of putative AS events at a genome-wide
scale. Affymetrix GeneChip Exon Arrays measure 1.4 million
data points interrogating over 1 million exon clusters. To date,
there is no standard procedure for the analysis of high-
throughput exon arrays, and methodological developments are
still needed [1,2].
Alternative splicing associated with a disease phenotype is
manifested by the presence of exons within a gene showing
differential expression between 2 (or more) disease groups [3]. A
common approach for the detection of AS is the calculation of
the splicing index (SI) [4]. This index can be used to characterize
splicing events in experimental designs including phenotypes with
2 conditions. The gene-level normalized exon intensity is definedby the ratio of the exon intensity to the gene intensity at a given
condition. The splicing index corresponds to the log ratio of the
normalized exon intensity in the first condition to the normalized
exon intensity in the second condition. If the expression level of an
exon does not vary over the 2 conditions, an SI of 0 is expected.
Conversely, extreme SI values would indicate the presence of puta-
tive AS. In practice, this index is often used either for the direct
screening of AS, or as a preliminary step of data transformation
needed in some advanced AS detection algorithms. The algorithm
MIDAS (Microarray Detection of Alternative Splicing) is based on
a similar concept of SI, testing the ratio of exon over gene expres-
sion using ANOVA related approaches [5]. Gaidatzis and colleagues
[6] discovered a systematic bias between gene expression and
alternative splicing. They showed that the higher the differential
expression and the more likely one detects AS. This overestimation
of AS was corrected by the newly developed algorithm COSIE
(Corrected Splices Indice for Exon array).
Another common approach for AS detection is the use of 2-way
ANOVA with interaction [7]. In this approach, 2 fixed effects are
modeled (experimental conditions, and gene effect) together with
an interaction term. A large change in splicing will result in a large
interaction term. Although commonly used, ANOVA-based algo-
rithms have some limitations, e.g. in cases where the number of
replicates is small. This results in a low power to detect AS.
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Fig. 1. Scheme of Dually Constrained Correspondence Analysis. Three tables are
used in DCCA: the main table of exon expression levels X together with a categorical
variable describing patient phenotypes (f1) and the within-gene exon-level
structures (f2). The signs in the margins indicate that the analysis is restricted
exon-wise () and constrained observation-wise (+).
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As an example, the algorithm FIRMA [8] identifies AS by detecting
outliers among residuals using a robust criterion (median absolute
deviation of the residuals). More recently, another gene-by-gene
approach was proposed, addressing the problem of AS detection
in the framework of robust linear modeling [9].
Most common approaches address the problem of AS detection
in a gene-by-gene manner, without taking into account potential
gene/exon interactions and/or co-variations. More satisfactory
methods addressing the AS problem in a multivariate fashion by
taking the whole benefit of the comprehensive information avail-
able in genome-wide exon arrays, are scarce. To date, only a hand-
ful of studies successfully applied multivariate approaches to
address the multi-dimensional challenge of genome-wide AS. In
this regards, a few methods based on singular value decomposition
(SVD) were proposed. For example, the concept of eigen-exons was
proposed as a promising tool for AS detection [10]. Another AS
screening tool was developed, based on the SVD of the residual
matrix from a robust additive model fit to probe selection region
[3]. In another publication, authors successfully used an SVD-
related approach, namely orthogonal projections to latent struc-
tures discriminant analysis (oPLS-DA), for the identification of AS
occurrences in transforming growth factorb linked to thoracic
aortic aneurysms [11].
Along with other ordination methods, correspondence analysis
(CA) has been successfully applied for the exploratory analysis of
high-throughput gene expression data. The flexibility of this
method makes it possible to integrate external information in the
form of linear constraints that can be applied both row-wise and
column-wise. This proved to be a powerful way to extract mean-
ingful patterns, and support the supervised interpretation of highly
multivariate data.
Several extensions of CA applied to gene expression microarray
data were recently proposed, covering unsupervised exploratory
methods [12,13], disease class prediction [14,15], and removal of
undesirable effects [16]. Although CA was classically developed
for the analysis of categorical variables, it was often extended to
positive continuous variables where CA-specific properties are
sought after [13].
More recently, RLQ analysis was proposed for the exploration of
transcription factor activity in microarray data [17]. RLQ is a spe-
cial form of correspondence analysis where constraints are applied
row-wise and column-wise to the main table of interest. This was
used for the interpretation of gene expression data in the light of
transcription factor activity.
The dual linear constraints applied in RLQ can also be useful for
the analysis of exon array data, where the main table of interest is
essentially structured row-wise by observation characteristics (e.g.
patients’ phenotypes) and column-wise by the within-gene exonic
structure. However, unlike RLQ, in order to identify splicing events,
one needs to investigate the within-gene exon-level variations.
This is done by partialling out the overall gene effect from the
exon-level expressions. This leads to a residual matrix of within-
gene variations, which is consecutively constrained by the
between-group phenotypic information used for the identification
of differential splicing events.
In this context, we propose a new implementation of dually
constrained CA. The innovation of the current approach relies on
the specific choice of the constraints: here CA is restricted gene-
wise (within-gene variations), and constrained observation-wise
(between-condition variations) (Fig. 1). This approach is a special
case of Dually Constrained Correspondence Analysis (the acronym
DCCA is used later) where one external factor defining blocks
among exons is used as a covariable (cofactor) and one factor
defining blocks among patients is used as an explanatory variable.
Our implementation of DCCA relates both to RLQ [18,17] wheretwo (sets of) positive constraints are applied row-wise and
column-wise, and internal correspondence analysis (a dual intra-
block CA) where two negative constraints (covariables) are applied
row-wise and column-wise to the main table of interest [19,20]. All
these approaches rely on the general framework of linearly con-
strained constrained correspondence analysis previously described
in psychometrics [21,22]. The novel DCCA implementation with its
gene-wise restriction and observation-wise constraint constitutes
an original tool for the analysis of exon array data that highlights
differences between patient groups that occur at the within-gene
level. To the best of our knowledge, this is the first time that this
specific implementation of DCCA is described and applied to a data
set from the biomedical field.
Using the general framework of CA for AS detection is mainly
motivated by two reasons. First, CA involves v2 metrics which
implies that gene and exon contributions are independent from
their absolute intensity [13,23]. This alleviates the bias reported
by the developers of the algorithm COSIE who demonstrated that
AS events are more prone to be detected in genes having high
intensity [6]. Second, resampling techniques can be applied to con-
strained CA methods including DCCA. This allows a better control
over the risk of false positives.
The aim of the current study is to give a detailed overview of
DCCA and demonstrate its performance for the identification of
putative AS in genome-wide exon array data. The manuscript is
organized as follows. In the first section, the theoretical aspects
of DCCA are summarized. In the Results, a motivating example
originated from thoracic oncology is used in order to demonstrate
the value of the method. The efficacy of DCCA is then compared
with other alternative approaches. In the final section, the advan-
tages and limitations of the method are discussed.
2. Materials and methods
2.1. Ordinary correspondence analysis
The core procedure in DCCA is correspondence analysis, a
powerful ordination method classically used for the analysis of
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of tables of positive or null values (e.g. genomics data). Ordinary
correspondence analyses are used to investigate the dependence
between rows and columns in a data set. Theoretical aspects
underlying CA can be summarized by defining the following:
 X the nm matrix of exon-level expression data (n samples, m
exons).
 P ¼ X=N the data matrix divided by its grand total
(N ¼Pni¼1
Pm
j¼1xij, the sum of all elements in X).
 r the ndim vector of row sums of P (row weights).
 c the mdim vector of column sums of P (column weights).
 Dr the n n diagonal matrix of row sums.
 Dc the mm diagonal matrix of column sums.
In correspondence analysis, the main matrix of interest is con-
verted into a v2 distance matrix after the following pre-
processing data transformation:
Z ¼ D1=2r ðP rcTÞD1=2c ð1Þ
Correspondence analysis performs the singular value decompo-
sition of Z:
Z ¼ UKVT ð2Þ
with K the k k (k ¼ rankðZÞ) diagonal matrix of singular values
associated with Z with k1 P   P kk > 0;U an n k matrix whose
columns are the left singular vectors of Z and V an m k matrix
whose columns are the right singular vectors of Z. The rows of U
and V are orthonormal with respect to Dr and Dc , respectively:
UTDrU ¼ VTDcV ¼ I ð3Þ
The principal components and row coordinates are given by
D1=2r U and D
1=2
r UK, respectively. The principal axes and column
coordinates are given by D1=2c V and D
1=2
c VK, respectively.
2.2. Dually constrained correspondence analysis
In DCCA, external information is introduced into ordinary CA by
using linear constraints on both rows and columns. More specifi-
cally, the transformation implies a variable-wise restriction, and
an observation-wise constraint. For the current application of
DCCA, we focused on the particular case where rows are structured
by one categorical variable defining blocks among observations
(phenotypes), and columns are structured by another categorical
variable defining blocks among variables (gene structure). Let us
define the following:
 M the n g matrix of dummy variables defining g blocks of
observations.
 H the m h matrix of dummy variables defining h blocks of
variables.
The observation-wise constraint is given by the projection
operator:
Or ¼MðMTDrMÞ1MTDr ð4Þ
Projecting on Or computes the means per block of observations
for each variable. This puts emphasis on between-block differ-
ences, i.e. focusing on between-patient phenotype variations.
The variable-wise restriction is given by the orthogonal projec-
tion operator:
Q c ¼ IHðHTDcHÞ
1
HTD1c ð5ÞProjecting on Q c subtracts the means per block of variables,
putting emphasis on within-block variations. This procedure elim-
inates the effect of the overall gene expression intensity levels thus
focusing on the within-gene exonic variations.
The last step consists in performing the SVD of:
Z ¼ D1=2r OrðP rcTÞQ TcD1=2c ¼ UKVT ð6Þ
with UTDrU
 ¼ VTDcV ¼ I
The principal components and row coordinates are given by
D1=2r U
 and D1=2r U
K, respectively. The principal axes and column
coordinates are given by D1=2c V
 and D1=2c V
K, respectively. The
contribution of each variable towards each DCCA axes is given by
DcðD1=2c VÞ
2
.
2.3. Bootstrapped-DCCA
Bootstrapping procedure was applied to DCCA in order to assess
the stability of the results, and provide a control over the risk of
false positive findings. The procedure used here follows a method-
ology described in ecological science [24,25]. Residuals of the
observation-wise constrained model are resampled with replace-
ment within the levels of the factor defining the blocks among
observations. DCCA is applied to a large set of bootstrapped sam-
ples (N ¼ 1000) and the distribution of the exon loadings on the
first axis of DCCA is infered. False positives are defined by the exon
loading crossing the value 0 more than 5% of times during the
bootstrap procedure.
2.4. Computational, statistical and graphical considerations
All analyses were implemented using the R statistical software
(version 3.1.2) [26] including the extension package ade4 [27], as
well as dedicated packages from the Bioconductor project [28]
such as the annotation package annmap (Homo sapiens database
version 78). Functions available in ade4 (including dudi.coa,
wca and bca) can theoretically be used to carry out DCCA. How-
ever, for reasons of computational efficiency due to the extensive
size of exon array data sets (generally including dozens/hundreds
of observations and up to 1.4 million variables), the DCCA algo-
rithm was substantially optimized and is available in the form of
a new R extension package (see Supplementary material). More
specifically, in the current implementation of DCCA, efficient com-
putations of the mean per group levels were used and the memory
consumption of operations involving very large objects was care-
fully monitored and optimized.
Graphical representation were done using the R package
ggplot2 [29]. When applied to cases where observations
(patients) are categorized into two groups, DCCA yield 1-
dimensional axes. The loadings (variable coordinates) on this
unique axis are used to rank the exons according to their contribu-
tion to the first DCCA axis (best AS candidates). Within-gene exonic
variations are depicted using separated correspondence analysis
biplots.
2.5. Gene functional annotations
Gene functional annotation tools including the web-services
DAVID [30] and GATHER [31] were used as a help for the biological
interpretation of results obtained by DCCA and other alternative
methods. These tools allow for gene enrichment analyses and help
to assess the biological relevance of large lists of genes. In order to
validate AS candidates predicted by DCCA and other alternative
methods, representative alternative splicing variants (RASV) were
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alternative splicing (H-DBAS, version 6) [32]. Further evidence of
alternative splicing or functionally characterized isoforms were
obtained by using knowledge databases including UniProtKB/
Swiss-Prot [33] and Ensembl [34].Table 1
Patients characteristics. The table summarizes the characteristics of patients included
in the current study. This includes a unique patient identifier (UPN), together with
age, gender, disease stage and disease stabilization at week 12. This last parameter
was used for alternative splicing detection.
UPN Age Gender Stage Disease stabilization
at week 122.6. Lung cancer data set
In order to demonstrate the current methodology, an oncolog-
ical data set originated from the Swiss Group for Clinical Cancer
Research was used (phase II trial SAKK 19/05; ClinicalTrials.gov:
NCT00354549). In this trial, 103 patients with advanced
non-small cell lung cancer (NSCLC) were enrolled, among which
101 were evaluable. Patients were treated using the combined
targeted therapy bevacizumab/erlotinib until disease progression
or unacceptable toxicity. The primary endpoint of this trial was
disease stabilization 12 weeks after initiation of therapy. This
endpoint was used in the current study to categorize patients
into responders vs. non-responders. Further detailed information
about the study design of the trial SAKK 19/05 can be found in
previous publications [35,36]. Bronchoscopic biopsies were taken
at baseline in 49 patients among which 42 were of suitable
quality for subsequent exon array analysis. The clinical trial as
well as the current translational substudy were approved by
the ethics committee of the canton of St. Gallen (EKSG 06/012).
Written informed consent for translational research was obtained
from all patients who agreed to have their clinical records used
in this study.2 69 M IV 0
23 53 F IV 0
38 58 F IV 0
49 56 M IV 1
51 70 F IIIB 0
55 55 F IV 0
56 61 F IV 1
57 66 F IV 0
58 46 F IV 0
60 64 F IV 1
61 61 F IV 1
63 48 F IIIB 0
64 64 M IV 1
65 67 F IV 0
67 53 M IV 1
68 63 M IV 0
69 66 F IIIB 0
70 35 M IV 12.7. Exon array analysis
RNA from whole bronchoscopic biopsy samples was extracted
and provided sufficient quality for microarray hybridization in 42
of 49 samples. Messenger RNAs were hybridized on Affymetrix
Human Exon 1.0 ST arrays (Affymetrix, Santa Clara, CA, USA) fol-
lowing standard recommendations from the manufacturer. This
microarray platform measures genome-wide exon-level expres-
sion in over 1.4 million probe sets. Raw data have been deposited
in NCBI’s Gene Expression Omnibus (GEO), and are accessible
through GEO Series accession number GSE37138. The exon level
probesets were pre-processed, quality checked and normalized
using the Robust Multi-array Average (RMA) procedure [37].74 61 M IV 1
75 61 M IV 0
76 51 F IV 1
77 54 M IV 1
78 63 F IV 1
80 44 F IV 0
81 55 M IV 0
82 58 M IV 1
83 53 F IV 0
84 55 F IV 1
87 74 M IV 1
88 78 M IV 0
90 69 F IV 1
91 68 M IV 0
93 56 F IV 1
94 49 F IV 1
95 64 M IV 1
96 77 M IV 0
97 68 F IV 0
98 64 F IV 1
99 48 M IV 1
101 66 M IV 0
102 59 F IV 1
103 72 F IV 12.8. Comparison with alternative approaches
The results obtained by DCCA were compared with those
obtained by 2-way ANOVAmodels, also known as analysis of splice
variation (ANOSVA) [7]. ANOSVA models are defined as follows
(Eq. (7)):
yijk ¼ lþ ai þ bj þ cij þ ijk ð7Þ
with yijk the intensity of exon k within gene i for the condition j;l
the overall effect, ai the effect of gene i;bj the effect of condition
j; cij the gene/condition interaction term and ijk the error term. Evi-
dence of splicing events is indicated by the presence of significant
interaction terms.
The second approach considered in this comparison is the
Microarray Dection of Alternative Splicing algorithm (MIDAS) [5]
implemented in the Affymetrix Power Tools (APT) [38]. The third
approach used in this comparison is the Corrected Splicing Indices
for Exon array algorithms (COSIE) [6].3. Results
3.1. Application of DCCA to the lung cancer data set
Exon-level expression intensity was measured from samples
obtained on 42 patients with late stage non-small cell lung cancer
treated by combined targeted therapy (bevacizumab + erlotinib). A
summary of patient characteristics is provided in Table 1. Patients
were categorized into responders (n ¼ 22) vs. non-responders
(n ¼ 20) according to their response to therapy (disease stabiliza-
tion yes/no) at week 12. Our analysis was limited to the core set
of 210,060 well characterized probesets. No additional filtering
was carried out. These probe sets were organized into 15,457
probe-selection regions (later referred to as genes).
The main table of exon expression levels, including 42 observa-
tions and 210,060 variables, was analyzed using DCCA. A categor-
ical variable defining the within-gene exonic structure was used to
restrict the analysis, whereas the binary variable (responders vs.
non-responders) was used to discriminate between the two
pre-defined patient phenotypes.
Table 2
List of the 100 exon splicing candidates identified by DCCA.
Exon ID Ensembl ID Gene symbol Description Sign of splicing RASV*
2858384 ENSG00000113448 PDE4D Phosphodiesterase 4D, cAMP-specific Responder 13
2858407 ENSG00000113448 PDE4D Phosphodiesterase 4D, cAMP-specific Responder 13
3268224 ENSG00000138152 BTBD16 BTB (POZ) domain containing 16 Non-responder 0
2779265 ENSG00000196616 ADH1B Alcohol dehydrogenase 1B (class I), beta polypeptide Non-responder 7
3174537 ENSG00000119125 GDA Guanine deaminase Non-responder 6
3409131 ENSG00000029153 ARNTL2 Aryl hydrocarbon receptor nuclear translocator-like 2 Responder 4
2858408 ENSG00000113448 PDE4D Phosphodiesterase 4D, cAMP-specific Responder 13
2509962 ENSG00000168280 KIF5C Kinesin family member 5C Responder 3
2502004 ENSG00000175497 DPP10 Dipeptidyl-peptidase 10 (non-functional) Responder 4
2692888 ENSG00000173702 MUC13 Mucin 13, cell surface associated Responder 0
3910454 ENSG00000019186 CYP24A1 Cytochrome P450, family 24, subfamily A, polypeptide 1 Responder 0
2790684 ENSG00000171557 FGG Fibrinogen gamma chain Responder 8
2561504 ENSG00000162951 LRRTM1 Leucine rich repeat transmembrane neuronal 1 Responder 3
3697153 ENSG00000103051 COG4 Component of oligomeric golgi complex 4 Non-responder 1
2912668 ENSG00000082293 COL19A1 Collagen, type XIX, alpha 1 Responder 3
3388378 ENSG00000082175 PGR Progesterone receptor Responder 0
3753981 ENSG00000275688 CCL15-CCL14 CCL15-CCL14 readthrough (NMD candidate) Non-responder 1
3409128 ENSG00000029153 ARNTL2 Aryl hydrocarbon receptor nuclear translocator-like 2 Responder 4
4018119 ENSG00000101938 CHRDL1 Chordin-like 1 Non-responder 4
2736280 ENSG00000163104 SMARCAD1 SWI/SNF-related, matrix-associated actin-dependent regulator of
chromatin, subfamily a, containing DEAD/H box 1
Responder 5
3467492 ENSG00000185046 ANKS1B Ankyrin repeat and sterile alpha motif domain containing 1B Responder 14
3140492 ENSG00000164764 SBSPON Somatomedin B and thrombospondin, type 1 domain containing Responder 0
3042786 ENSG00000105997 HOXA3 Homeobox A3 Responder 3
3398119 ENSG00000170322 NFRKB Nuclear factor related to kappaB binding protein Responder 0
3934139 ENSG00000275993 CU639417.1 NA Non-responder 0
2971732 ENSG00000111879 FAM184A Family with sequence similarity 184, member A Non-responder 6
3832873 ENSG00000188505 NCCRP1 Non-specific cytotoxic cell receptor protein 1 homolog (zebrafish) Non-responder 0
2423858 ENSG00000137962 ARHGAP29 Rho GTPase activating protein 29 Responder 4
3261499 ENSG00000166197 NOLC1 Nucleolar and coiled-body phosphoprotein 1 Non-responder 4
3411757 ENSG00000018236 CNTN1 Contactin 1 Responder 3
3626323 ENSG00000128918 ALDH1A2 Aldehyde dehydrogenase 1 family, member A2 Non-responder 1
3581916 ENSG00000211896 IGHG1 Immunoglobulin heavy constant gamma 1 (G1m marker) Responder 0
3936168 ENSG00000099954 CECR2 Cat eye syndrome chromosome region, candidate 2 Responder 2
2794652 ENSG00000150625 GPM6A Glycoprotein M6A Non-responder 4
3429191 ENSG00000136011 STAB2 Stabilin 2 Responder 0
3290038 ENSG00000150275 PCDH15 Protocadherin-related 15 Responder 4
3701484 ENSG00000166473 PKD1L2 Polycystic kidney disease 1-like 2 Non-responder 6
2827120 ENSG00000155324 GRAMD3 GRAM domain containing 3 Responder 3
2739800 ENSG00000073331 ALPK1 Alpha-kinase 1 Responder 5
3429215 ENSG00000136011 STAB2 Stabilin 2 Responder 0
3308338 ENSG00000151892 GFRA1 GDNF family receptor alpha 1 Responder 2
2562440 ENSG00000168878 SFTPB Surfactant protein B Responder 0
3868772 ENSG00000167755 KLK6 Kallikrein-related peptidase 6 Non-responder 7
3816736 ENSG00000104953 TLE6 Transducin-like enhancer of split 6 Responder 3
3121944 ENSG00000183117 CSMD1 CUB and Sushi multiple domains 1 Non-responder 7
3232410 ENSG00000067057 PFKP Phosphofructokinase, platelet Non-responder 6
3004687 ENSG00000197008 ZNF138 Zinc finger protein 138 Responder 5
3634868 ENSG00000058335 RASGRF1 Ras protein-specific guanine nucleotide-releasing factor 1 Responder 5
3641887 ENSG00000140471 LINS Lines homolog (Drosophila) Non-responder 0
3416705 ENSG00000172551 MUCL1 Mucin-like 1 Non-responder 0
2362212 ENSG00000158481 CD1C CD1c molecule Responder 3
2732980 ENSG00000138756 BMP2K BMP2 inducible kinase Responder 3
2387317 ENSG00000198626 RYR2 Ryanodine receptor 2 (cardiac) Responder 2
3848519 ENSG00000104921 FCER2 Fc fragment of IgE, low affinity II, receptor for (CD23) Responder 8
3268154 ENSG00000138162 TACC2 Transforming, acidic coiled-coil containing protein 2 Non-responder 15
2496908 ENSG00000115590 IL1R2 Interleukin 1 receptor, type II Responder 1
2423643 ENSG00000023909 GCLM Glutamate-cysteine ligase, modifier subunit Responder 0
3490916 ENSG00000102837 OLFM4 Olfactomedin 4 Non-responder 2
3114140 ENSG00000147689 FAM83A Family with sequence similarity 83, member A Responder 0
2956945 ENSG00000170927 PKHD1 Polycystic kidney and hepatic disease 1 (autosomal recessive) Non-responder 3
3030145 ENSG00000174469 CNTNAP2 Contactin associated protein-like 2 Responder 2
2456251 ENSG00000092978 GPATCH2 G patch domain containing 2 Non-responder 3
3505506 ENSG00000027001 MIPEP Mitochondrial intermediate peptidase Non-responder 2
2377321 ENSG00000117322 CR2 Complement component (3d/Epstein Barr virus) receptor 2 Responder 3
3264888 ENSG00000148702 HABP2 Hyaluronan binding protein 2 Responder 2
4030114 ENSG00000114374 USP9Y Ubiquitin specific peptidase 9, Y-linked Non-responder 0
2468367 ENSG00000134321 RSAD2 Radical S-adenosyl methionine domain containing 2 Responder 0
3910444 ENSG00000019186 CYP24A1 Cytochrome P450, family 24, subfamily A, polypeptide 1 Non-responder 0
3341092 ENSG00000078124 ACER3 Alkaline ceramidase 3 Non-responder 9
3113414 ENSG00000187955 COL14A1 Collagen, type XIV, alpha 1 Responder 4
3707765 ENSG00000167842 MIS12 MIS12 kinetochore complex component Responder 2
3089746 ENSG00000008853 RHOBTB2 Rho-related BTB domain containing 2 Non-responder 3
(continued on next page)
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Table 2 (continued)
Exon ID Ensembl ID Gene symbol Description Sign of splicing RASV*
3726783 ENSG00000108848 LUC7L3 LUC7-like 3 (S. cerevisiae) Responder 4
3221652 ENSG00000148229 POLE3 Polymerase (DNA Directed), Epsilon 3, Accessory Subunit Non-responder 0
2689663 ENSG00000181722 ZBTB20 Zinc finger and BTB domain containing 20 Responder 7
2667198 ENSG00000163512 AZI2 5-Azacytidine induced 2 Non-responder 5
2779240 ENSG00000196616 ADH1B Alcohol dehydrogenase 1B (class I), beta polypeptide Responder 7
3864383 ENSG00000124466 LYPD3 LY6/PLAUR domain containing 3 Non-responder 2
3159558 ENSG00000107104 KANK1 KN motif and ankyrin repeat domains 1 Responder 5
2949973 ENSG00000204296 C6orf10 Chromosome 6 open reading frame 10 Responder 9
3058262 ENSG00000187391 MAGI2 Membrane associated guanylate kinase, WW and PDZ domain containing 2 Responder 7
3507223 ENSG00000122025 FLT3 Fms-related tyrosine kinase 3 Responder 3
3336904 ENSG00000172932 ANKRD13D Ankyrin repeat domain 13 family, member D Non-responder 7
3824435 ENSG00000167483 FAM129C Family with sequence similarity 129, member C Responder 6
2566863 ENSG00000144218 AFF3 AF4/FMR2 family, member 3 Responder 1
2634087 ENSG00000144815 NXPE3 Neurexophilin and PC-esterase domain family, member 3 Responder 0
3039211 ENSG00000006468 ETV1 Ets variant 1 Responder 9
2886276 ENSG00000184347 SLIT3 Slit homolog 3 (Drosophila) Responder 4
2451622 ENSG00000133063 CHIT1 Chitinase 1 (chitotriosidase) Responder 6
3523568 ENSG00000102466 FGF14 Fibroblast growth factor 14 Responder 2
3791796 ENSG00000206075 SERPINB5 Serpin peptidase inhibitor, clade B (ovalbumin), member 5 Responder 4
3581917 ENSG00000211896 IGHG1 Immunoglobulin heavy constant gamma 1 (G1m marker) Responder 0
3466641 ENSG00000165972 CCDC38 Coiled-coil domain containing 38 Non-responder 2
3340002 ENSG00000021300 PLEKHB1 Pleckstrin homology domain containing, family B (evectins) member 1 Non-responder 8
3847009 ENSG00000105355 PLIN3 Perilipin 3 Non-responder 2
2350490 ENSG00000116299 KIAA1324 KIAA1324 Non-responder 7
3079304 ENSG00000181652 ATG9B Autophagy related 9B Non-responder 4
3175628 ENSG00000197969 VPS13A Vacuolar protein sorting 13 homolog A (S. cerevisiae) Non-responder 4
3830396 ENSG00000012124 CD22 CD22 Molecule Non-responder 6
2445999 ENSG00000116194 ANGPTL1 Angiopoietin-like 1 Responder 3
⁄ Representative alternative splicing variants extracted from H-DBAS.
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exons having the highest contribution on the first axis of DCCA.
A bootstrap resampling procedure was carried out in order to
ensure the stability of the contribution of the best candidates.
Splicing candidates reveal a series of genes related to tumorige-
nesis (SFTPB), cell adhesion (STAB2, PCDH15, HABP2), tumor
aggressiveness (ARNTL2), apoptosis, proliferation and differentia-
tion (PDE4D, FLT3, IL1R2), cell invasion (ETV1), as well as tumor
growth (OLFM4, FGF14), tumor necrosis (AFF3), and tumor sup-
pression (TUSC3, CSMD1, RHOBTB2, SERPINB5, TACC2) [39,40].
Indication of known alternative splicing or genes with functionally
characterized isoforms was found in a majority of candidates as
reported in the literature and in knowledge databases (H-DBAS,
Ensembl, UniProtKB/Swiss-Prot) (Table 3). Diagnostic markers ofTable 3
Gene enrichment analysis of the gene list generated by DCCA in different functional
categories. The following annotations retrieved by the webtool DAVID included: Gene
ontology, KEGG pathways.
Source Annotation Genes p-value
Gene ontology
(biological
process)
GO:0007155: cell
adhesion
CD22, LYPD3, COL14A1,
COL19A1, CNTN1,
CNTNAP2, HABP2,
OLFM4, PKHD1,
PCDH15, STAB2
0.0028
GO:0022610:
biological
adhesion
CD22, LYPD3, COL14A1,
COL19A1, CNTN1,
CNTNAP2, HABP2,
OLFM4, PKHD1,
PCDH15, STAB2
0.0028
KEGG pathway hsa04640:
Hematopoietic
cell lineage
CD1C, CD22, FCER2, CR2,
FLT3, IL1R2
0.0024
BBID-Biological
Biochemical
Image
Database –
pathway
6.CD23
engagement:
activation,
differentiation,
cell death
FCER2, CR2, IGHG1,
NOLC1
<0.033metastasis and micrometastasis (MUCL1, GHOSH) were also found.
Prognostic markers in lung carcinomas including CYP24A1 and
ZBTB20 were identified. Genes associated with the mechanism of
action of both targeted therapies (bevacizumab and erlotinib) were
clearly identified. Genes functionally related to angiogenesis
included PDED4 [41], CHRDL1, STAB2 and ANGPTL1. Mechanisms
of action associated with tyrosine kinases included regulation of
tyrosine phosporylation (CD22, PFKP, FLT3) [42], GTPase activity
(ARHGAP29, NOLC1, KANK1). Genes associated with drug resis-
tance were also found (MAGI2, GCLM).
Among the 93 unique genes identified by DCCA, 74 showed the
presence of representative alternative splicing variants (80%) as
defined in the H-DBAS database.
The gene PDE4D, having the highest contribution on the first
DCCA dimension is represented in Fig. 2. This figure displays in
parallel the AS expression plot and the correspondence analysis
biplot counterpart. The exon-specific discrepancy between the
expression levels of the two disease-related phenotypes (respon-
ders vs. non-responders) is shown in the left panel. This graphical
representation allows detection of putative AS events for specific
exons in which inconsistent expression levels are observed. In
the CA counterpart, AS events are detected by picking outlying
exons with extreme coordinates (right panel). These exons typi-
cally show high within-gene variations and strong discrimination
between responders vs. non-responders. PDE4 encodes for
phosphodiesterase-4 which promotes proliferation and angiogene-
sis in lung cancer [41]. Several isoforms including PDE4D have
been characterized which respond to hypoxia. Silencing of PDE4D
reduced human lung tumor cell proliferation and colony formation.
3.2. Stability of the results
The bootstrapped distribution of the loadings of the 100 best
AS candidates is shown in Fig. 3. Unreliable AS findings are
represented by a dashed line. The occurred in five candidates
including exons 2692888 (MUC13), 2790684 (FGG), 3634868
(RASGRF1), 3341092 (ACER3), 3079304 (ATG9B).
F. Baty et al. / Journal of Biomedical Informatics 58 (2015) 175–185 1813.3. Comparison with current standard methods
DCCA results were compared with the ones obtained from com-
mon alternative approaches, including the ANOSVA, MIDAS and2
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Fig. 2. Alternative splicing expression plots and separated correspondence analysis bip
exons within PDE4D for each condition (red and blue for responders and non-responders,
The right panel displays the biplot representation (scores and loadings) of separated corr
dispersion of the exon coordinates (segments) is summarized by a dotted ellipse, which e
plain colored dots. The dispersion of the observations is represented by means of emp
responders, respectively).
Table 4
Comparison with other alternative splicing methods. The following four methods are c
annotations and pathway enrichment analyses are based on the DAVID functional annota
DCCA COSIE
# AS candidates 100 100
# unique genes 93 98
Common genes with DCCA – 6%
Characterized AS in the H-
DBAS database
80% 77%
Pathway analysis
Functional annotation
clusters
Cluster 1 (ES = 2.55): signal, signal
peptide, glycoprotein, glycosylation
site, Secreted, disulfide site/bond,
extracellular space/region
Cluster 1 (ES
phosphoprote
activity, tyros
phosphatase,
dephosphory
Cluster 2 (ES = 1.96): domain:EGF-like
(2, 1, 3), EGF, EGF-like region
Cluster 2 (ES
apparatus
Cluster 3 (ES = 1.92): cell adhesion,
biological adhesion
Cluster 3 (ES
rich repeat, C
flanking regio
KEGG pathway Hematopoietic cell lineage
(map04640: p ¼ 6:1 105)
–
Alternative splicing 54 genes (p ¼ 4:1 105) 50 genes (p ¼
Splice variant 54 genes (p ¼ 4:5 105) 50 genes (p ¼
Execution time (sec)a 1.153 4.629
a Performed on a laptop Lenovo Yoga 2 Pro, Intel CoreTM i7-4510U CPU 2.00 GHz  4,COSIE algorithms. For the sake of this comparison, 100 best AS can-
didates obtained by each of the four approaches where considered.
Table 4 gives an overview of this comparison. Two aspects were
particularly investigated: the biological relevance of the genes sub-−0.10
−0.05
0.00
0.05
0.10
0.15
−0.3 −0.2 −0.1 0.0 0.1 0.2
CA axis 1
C
A
 a
xi
s 
2
Separated Correspondence Analysis
lots of gene PDE4D. The left panel displays the exon expression intensities of each
respectively). The alternative splicing candidates are identified by a vertical red line.
espondence analysis (two first axes) when only including PDE4D exons. The normal
nables to detect extreme values corresponding to AS candidates and represented by
ty colored dots together with convex hulls (red and blue for responders and non-
onsidered in this comparison: DCCA, COSIE, MIDAS and ANOSVA. Functional gene
tion tool.
MIDAS ANOSVA
100 100
95 98
8% 22%
82% 68%
= 1.52):
in phosphatase
ine-specific
lation
Cluster 1 (ES = 1.31):
immunoglobulin
Cluster 1 (ES = 1.17):
cytoplasmic, membrane,
extracellular, transmembrane,
glycoprotein, glycosylation
: 1.11): golgi Cluster 2 (ES = 1.17):
cytoplasmic,
transmembrane region,
glycoprotein,
glycosylation
Cluster 2 (ES = 1.17):
intermediate filament protein,
structural molecule activity,
cytoskeletal part
= 0.88): leucine-
ystein-rich
n
Cluster 3 (ES = 1.14):
signal, extracellular,
glycoprotein,
glycosylation, disulfide
bond
Cluster 3 (ES = 1.09):
sugar/carbohydrate binding,
Lectin
– –
1:5 103) 46 genes
(p ¼ 2:6 102)
46 genes (p ¼ 6:0 103)
1:5 103) 45 genes
(p ¼ 4:4 102)
46 genes (p ¼ 6:3 103)
9.197 53.845
8 GB RAM.
Fig. 3. Bootstrapped DCCA. The bootstrap distribution of the loadings of the 100 best alternative splicing candidates identified by DCCA is presented. Each AS candidate is
represented by a line showing the range (min–max) of the loadings on the first DCCA axis. The filled square represents the median bootstrap estimate. The color code
describes whether a given exon is over-represented in responders (blue) or in non-responders (red). Dashed lines are depicted whenever a splicing candidate is considered
unreliable (loadings changing signs in more than 5% of the bootstrapped samples).
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established gold standard method exists for the determination of
true splicing events, our results were validated using knowledge
databases and literature findings. Furthermore, the execution time
required by each of the four methods is reported. DCCA required
slightly over 1 s of execution time, whereas the three alternative
approaches needed between 4.6 and up to 53 s to run on the cur-
rent data set.
The result overlap between the four methods is summarized in
Fig. 4. The AS candidates identified by DCCA overlapped in 22%
with the candidates from ANOSVA, whereas only 8% of candidates
overlapped with the ones from MIDAS, and 6% with the ones from
COSIE. Overall, we could identify two clusters of methods among
the four used in this comparison: DCCA and ANOSVA which shared
22% of common AS candidates and COSIE and MIDAS which shared
33% of common AS candidates. Over 80% of AS candidates were
functionally characterized when using the H-DBAS database both
regarding the MIDAS and DCCA algorithms, whereas the COSIE
and ANOSVA approaches showed a lower percentage (77% and
68%, respectively). Keywords and features including ‘‘Alternative
splicing” and ‘‘Splice variant” were significantly enriched in the
DCCA list of AS candidates (involving 58% of genes, p ¼ 4 105)
as compared to the other competing methods for which the asso-
ciation was weaker.
With regard to the biological relevance, DCCA provided genes
that belonged to various functional annotation clusters. The main
cluster is related to signal and energy process which can be associ-
ated with the mechanisms of action of EGFR-TKI [43]. A second
cluster directly relates the AS candidates to epidermal growth
factor-like domains which play an important role in the growth
and proliferation of tumor cells. A third functional annotation clus-
ter is specifically related to cell adhesion, another important pro-
cess in cancer progression and metastasis. Functional annotation
related to the AS candidates obtained with the COSIE algorithm
reveal splicing event related to tyrosine-specific phosphorylation,
golgi apparatus and leucine-rich repeat. Functional annotation
clusters derived from the AS candidates obtained with MIDAS
include immunoglobulin, cytoplasmic transmembrane region and
glycoprotein, as well as signal and disulfide bond. Annotation clus-
ters derived from the ANOSVA approach highlight cytoplasmic,
membrane, and transmembrane compounds together withDCCA
SADIM
Fig. 4. Venn diagram representing the overlap betweeglycosylation process, as well as intermediate filament and sugar/-
carbohydrate binding.
4. Discussion
The interpretation of CA is facilitated by applying linear con-
straints both observation- and variable-wise. Two approaches (also
known as reparametrization and null-space methods) are classically
used to incorporate these constraints either positively or nega-
tively (effect removal) to correspondence analysis [21,22,16],
resulting in a variety of CA-related methods. In the current work,
the natural choice was to apply a negative gene-wise constraint
in order to remove the overall gene effect and focus on the
within-gene (inter-exon) variability, together with a positive
observation-wise constraint in order to focus on the between-
group effect. This pre-processing technique proved to be suitable
for the identification of AS events.
Our approach differs from the classically used analysis of
splicing variations in the sense that all exons from all genes are
considered simultaneously in DCCA. Simpler methods limited to
gene-by-gene analyses (such as 2-way ANOVA) do not take into
account genes interactions which occur whenever genes are linked
into functional pathways. DCCA addresses the genome-wide alter-
native splicing problem in a more satisfying multivariate manner
by applying a dual constraint in one single computationally effi-
cient step. This theoretical difference may explain why we found
a relatively poor overlap between the AS candidates found with
our approach and the 3 other approaches (which all detect AS
events in a univariate manner). Interestingly, two groups of meth-
ods showed a higher percentage of overlapping AS candidates:
DCCA and ANOSVA (22%) vs. COSIE and MIDAS (33%). The first
group of methods includes underlying linear regression procedures
(gene-by-gene multiple linear regression with interaction in
ANOSVA; linear constraints in DCCA), whereas the second group
of methods is based on the (corrected) splicing index approach.
Another factor influencing the detection of AS events, is the rate
of true-positive candidates. Exon arrays are known to generate
false-positives AS candidates and different methods are unequally
affected by these spurious findings. In DCCA, false-positives were
controled using bootstrap resampling procedures. Other solutions
which consist in carrying out a more stringent pre-selection ofCOSIE
AVSONA
n AS candidates obtained from the four methods.
184 F. Baty et al. / Journal of Biomedical Informatics 58 (2015) 175–185genes/exons based on their signal intensity exist. However, in the
current work this was avoided in order to prevent the use of
arbitrary cut-offs for gene/exon selection.
In conclusion, DCCA provides a simple way to identify putative
AS events from genome-wide exon-array data. In comparison with
alternative approaches, DCCA proved to provide results which are
biologically relevant and with strong evidence of AS. Our results
provide new insights in the understanding of alternative splicing
events related to the response to targeted therapy in NSCLC and
allow for the discovery of novel prognostic biomarkers. AS candi-
dates identified by DCCA involve genes associated with tumorige-
nesis including all aspects of tumor biology as well as phenomena
occurring in the tumor microenvironment. Functional studies are
needed in order to confirm the clinical relevance of our findings,
and further understand the regulatory processes involved in these
splicing events.Conflict of interest
None declared.
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